Phenotypical analysis, relation to malignancy and prognostic relevance of ICOS + T regulatory and dendritic cells in patients with gliomas

Journal of Neuroimmunology

Volumn 264, Issue 1-2, 2013, Pages 84-90

  Gousias, Konstantinos ^a   von Ruecker, Alexander ^a   Voulgari, Paraskevi ^b   Simon, Matthias ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

DC based immunotherapy; Glioblastomas; ICOS; Mature dendritic cells; T regulatory cells

Indexed keywords

DEXAMETHASONE; INDUCIBLE T CELL COSTIMULATOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; MALE; MYELOID DENDRITIC CELL; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE SUBPOPULATION;

DC-BASED IMMUNOTHERAPY; GLIOBLASTOMAS; ICOS; MATURE DENDRITIC CELLS; T REGULATORY CELLS;

ADULT; AGED; ANTIGENS, CD; BRAIN NEOPLASMS; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GLIOMA; HUMANS; INDUCIBLE T-CELL CO-STIMULATOR PROTEIN; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PHENOTYPE; SURVIVAL ANALYSIS; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84886794709     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.09.001     Document Type: Article

References (51)

1. Almand B., Resser J.R., Lindman B., Nadaf S., Clark J.I., Kwon E.D., Carbone D.P., Gabrilovich D.I. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 2000, 6:1755-1766.
2. Ardon H., Van Gool S.W., Verschuere T., Maes W., Fieuws S., Sciot R., Wilms G., Demaerel P., Goffin J., Van Calenbergh F., Menten J., Clement P., Debiec-Rychter M., De Vleeschouwer S. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol. Immunother. 2012, 61(11):2033-2044.
3. Autissier P., Soulas C., Burdo T.H., Williams K.C. Evaluation of a 12-color flow cytometry panel to study lymphocyte, monocyte, and dendritic cell subsets in humans. Cytometry A 2010, 77(5):410-419.
4. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18:767-811.
5. Boon T., Coulie P.G., Van den Eynde B.J., van der Bruggen P. Human T cell responses against melanoma. Annu. Rev. Immunol. 2006, 24:175-208.
6. Cho D.Y., Lin S.Z., Yang W.K., Hsu D.M., Lee H.C., Lee W.Y., Liu S.P. Recent advances of dendritic cells (DCs)-based immunotherapy for malignant gliomas. Cell Transplant. 2009, 18(9):977-983.
7. Cid M.C., Campo E., Ercilla G., Palacin A., Vilaseca J., Villalta J., Ingelmo M. Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunological activation markers in temporal arteritis. Influence of corticosteroid treatment. Arthritis Rheum. 1989, 32(7):884-893.
8. Conrad C., Gregorio J., Wang Y.H., Ito T., Meller S., Hanabuchi S., Anderson S., Atkinson N., Ramirez P.T., Liu Y.J., Freedman R., Gilliet M. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS co-stimulation of Foxp3+ T regulatory cells. Cancer Res. 2012, 72(20):5240-5249.
9. Della Bella S., Gennaro M., Vaccari M., Ferraris C., Nicola S., Riva A., Clerici M., Greco M., Villa M.L. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br. J. Cancer 2003, 89(8):1463-1472.
10. Dimitrov S., Benedict C., Heutling D., Westermann J., Born J., Lange T. Cortisol and epinephrine control opposing circadian rhythms in T cell subsets. Blood 2009, 113(21):5134-5143.
11. Dix A.R., Brooks W.H., Roszman T.L., Morford L.A. Immune defects observed in patients with primary malignant brain tumors. J. Neuroimmunol. 1999, 100(1-2):216-232.
12. El Andaloussi A., Han Y., Lesniak M.S. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J. Neurosurg. 2006, 105(3):430-437.
13. Erdman S.E., Poutahidis T. Cancer inflammation and regulatory T cells. Int. J. Cancer 2010, 15(127(4)):768-779.
14. Fecci P.E., Mitchell D.A., Whitesides J.F., Xie W., Friedman A.H., Archer G.E., Herndon J.E., Bigner D.D., Dranoff G., Sampson J.H. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006, 66(6):3294-3302.
15. Fong L., Engleman E.G. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 2000, 18:245-273.
16. Gabrilovich D.I., Corak J., Ciernik I.F., Kavanaugh D., Carbone D.P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. 1997, 3(3):483-490.
17. Gousias K., Markou M., Arzoglou V., Voulgaris S., Vartholomatos G., Kostoula A., Voulgari P., Polyzoidis K., Kyritsis A.P. Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy. J. Neuroimmunol. 2010, 14(226(1-2)):136-142.
18. Hall J.R., Short S.C. Management of glioblastoma multiforme in HIV patients: a case series and review of published studies. Clin. Oncol. 2009, 21:591-597.
19. Heimberger A.B., Abou-Ghazal M., Reina-Ortiz C., Yang D.S., Sun W., Qiao W., Hiraoka N., Fuller G.N. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin. Cancer Res. 2008, 15(14(16)):5166-5172.
20. Hirooka S., Yanagimoto H., Satoi S., Yamamoto T., Toyokawa H., Yamaki S., Yui R., Inoue K., Michiura T., Kwon A.H. The role of circulating dendritic cells in patients with unresectable pancreatic cancer. Anticancer. Res. 2011, 31(11):3827-3834.
21. Hoffmann T.K., Müller-Berghaus J., Ferris R.L., Johnson J.T., Storkus W.J., Whiteside T.L. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin. Cancer Res. 2002, 8(6):1787-1793. (Erratum in: Clin. Cancer Res.;9(1):441).
22. Hughes M.A., Parisi M., Grossman S., Kleinberg L. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62(5):1423-1426.
23. Humphries W., Wei J., Sampson J.H., Heimberger A.B. The role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg. Clin. N. Am. 2010, 21(1):125-137.
24. Ito T., Hanabuchi S., Wang Y.H., Park W.R., Arima K., Bover L., Qin F.X., Gilliet M., Liu Y.J. Two functional subsets of Foxp3+ regulatory T cells in human thymus and periphery. Immunity 2008, 28(6):870-880.
25. Jacobs J.F., Idema A.J., Bol K.F., Grotenhuis J.A., de Vries I.J., Wesseling P., Adema G.J. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J. Neuroimmunol. 2010, 25(225(1-2)):195-199.
26. Kawakami Y., Rosenberg S.A. Human tumor antigens recognized by T-cells. Immunol. Res. 1997, 16(4):313-339.
27. Male D., Brostoff J., Roth D. Roitt I. Immunology 2006, 354-355. Elsevier. 7th edition.
28. Matasić R., Dietz A.B., Vuk-Pavlović S. Dexamethasone inhibits dendritic cell maturation by redirecting differentiation of a subset of cells. J. Leukoc. Biol. 1999, 66(6):909-914.
29. Menetrier-Caux C., Montmain G., Dieu M.C., Bain C., Favrot M.C., Caux C., Blay J.Y. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998, 15(92(12)):4778-4791.
30. Migliorati G., Bartoli A., Nocentini G., Ronchetti S., Moraca R., Riccardi C. Effect of dexamethasone on T-cell receptor/CD3 expression. Mol. Cell. Biochem. 1997, 167(1-2):135-144.
31. Moser M., De Smedt T., Sornasse T., Tielemans F., Chentoufi A.A., Muraille E., Van Mechelen M., Urbain J., Leo O. Glucocorticoids down-regulate dendritic cell function in vitro and in vivo. Eur. J. Immunol. 1995, 25(10):2818-2824.
32. Mougiakakos D., Choudhury A., Lladser A., Kiessling R., Johansson C.C. Regulatory T cells in cancer. Adv. Cancer Res. 2010, 107:57-117.
33. Nishikawa H., Sakaguchi S. Regulatory T cells in tumor immunity. Int. J. Cancer 2010, 15(127(4)):759-767.
34. Piemonti L., Monti P., Allavena P., Sironi M., Soldini L., Leone B.E., Socci C., Di Carlo V. Glucocorticoids affect human dendritic cell differentiation and maturation. J. Immunol. 1999, 1(162(11)):6473-6481.
35. Pinzon-Charry A., Ho C.S., Laherty R., Maxwell T., Walker D., Gardiner R.A., O'Connor L., Pyke C., Schmidt C., Furnival C., López J.A. A population of HLA-DR+ immature cells accumulates in the blood dendritic cell compartment of patients with different types of cancer. Neoplasia 2005, 7(12):1112-1122.
36. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 2010, 10(7):490-500.
37. Savary I., Debras E., Dardevet D., Sornet C., Capitan P., Prugnaud J., Mirand P.P., Grizard J. Effect of glucocorticoid excess on skeletal muscle and heart protein synthesis in adult and old rats. Br. J. Nutr. 1998, 79(3):297-304.
38. Scanlan M.J., Simpson A.J., Old L.J. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004, 23(4):1.
39. Sombroek C.C., Stam A.G., Masterson A.J., Lougheed S.M., Schakel M.J., Meijer C.J., Pinedo H.M., van den Eertwegh A.J., Scheper R.J., de Gruijl T.D. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 2002, 1(168(9)):4333-4343.
40. Sonabend A.M., Rolle C.E., Lesniak M.S. The role of regulatory T cells in malignant glioma. Anticancer. Res. 2008, 28(2B):1143-1150.
41. Tada M., de Tribolet N. Immunobiology of malignant gliomas. J. Clin. Neurosci. 1996, 3(2):102-113.
42. Takagi Y., Kikuchi T., Nimura M., Ohno T. Effects of glucocorticoids on antitumor effects of immunizations with fusions of dendritic and tumor cells. Anticancer. Res. 2003, 23(3B):2553-2558.
43. Troy A.J., Summers K.L., Davidson P.J., Atkinson C.H., Hart D.N. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res. 2000, 6(5):1755-1766.
44. Van Gool S., Maes W., Ardon H., Verschuere T., Van Cauter S., De Vleeschouwer S. Dendritic cell therapy of high-grade gliomas. Brain Pathol. 2009, 19(4):694-712.
45. Vieira P.L., Kaliński P., Wierenga E.A., Kapsenberg M.L., de Jong E.C. Glucocorticoids inhibit bioactive IL-12p70 production by in vitro-generated human dendritic cells without affecting their T cell stimulatory potential. J. Immunol. 1998, 161:5245-5251.
46. Vocanson M., Rozieres A., Hennino A., Poyet G., Gaillard V., Renaudineau S., Achachi A., Benetiere J., Kaiserlian D., Dubois B., Nicolas J.F. Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells. J. Allergy Clin. Immunol. 2010, 126(2):280-289.
47. Wan Y.Y. Regulatory T cells: immune suppression and beyond. Cell. Mol. Immunol. 2010, 7(3):204-210.
48. Wilke C.M., Wu K., Zhao E., Wang G., Zou W. Prognostic significance of regulatory T cells in tumor. Int. J. Cancer 2010, 127(4):748-758.
49. (accessed 08/07/2013). http://www.who.int/hiv/pub/guidelines.
50. Xu F., Li D., Zhang Q., Fu Z., Zhang J., Yuan W., Chen S., Pang D., Li D. ICOS gene polymorphisms are associated with sporadic breast cancer: a case-control study. BMC Cancer 2011, 11:392.
51. Zisakis A., Piperi C., Themistocleous M.S., Korkolopoulou P., Boviatsis E.I., Sakas D.E., Patsouris E., Lea R.W., Kalofoutis A. Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients. Cytokine 2007, 39(2):99-105.